Importantly, our findings suggest that the degradation of Pml or the selective inhibition of Pml-induced factors, or even their combination, may be beneficial for the eradication of minimal residual disease in CML and AML (Fig. 6d). The gene discussed is PML; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.